Trials / Completed
CompletedNCT05729594
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is being performed to compare the systemic pharmacokinetic profiles of T4032 and Lumigan 0.01% given that T4032 has a different formulation (in terms of excipients) from the reference product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost Ophthalmic | eyedrops |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
- First posted
- 2023-02-15
- Last updated
- 2023-11-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05729594. Inclusion in this directory is not an endorsement.